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INTRODUCTION
The shift in asthma prevalence and treatment from male to female predominance during the pubertal years (1) (2) (3) (4) supports an association between asthma and puberty. The first report on asthma as a predictor of timing of puberty, including pubertal staging, was published four decades ago (5) . Yet, as subsequent reports remain collectively inconclusive (5) (6) (7) (8) (9) (10) , this topic remains of current interest. Amongst boys, some (5), but not all (10) findings support that those with asthma may begin puberty later than those without asthma. Amongst girls, those with asthma may reach menarche (a marker of sexual maturation) at an earlier (6, 9) or later (7) age compared to those without asthma. Moreover, inhaled corticosteroids (ICS), the frontline therapy for asthma treatment since the 1970s, may further delay puberty amongst both sexes if given at high daily doses (11) .
Notwithstanding the common use of ICS as a treatment for asthma, there is also concern about the effects of ICS on height and growth. In a recently published review, orally inhaled ICS use by pre-pubertal children was found to be associated with short-term delayed growth in some, but not all randomised controlled trials (12) . Inconsistent findings may be partly attributable to different treatments, including duration and dosage (12) . In the one study with follow-up through adulthood, those who had used ICS in childhood averaged 1.2 cm shorter than those exposed to a placebo, a difference which was statistically significant, though likely not clinically relevant (13) . But, the pubertal years are characterised by substantial physiological changes, including growth (14), thereby mandating an understanding of the associations between ICS and growth during this time. ICS do not appear to be associated with pubertal staging (15). Associations between ICS and height during the pubertal years are collectively inconclusive. For example, some authors have reported that, compared to healthy controls, both asthma and ICS are associated with shorter height (11, 16) , particularly at doses >400 μg per day (8) . In contrast, other authors have not found statistically significant associations between asthma and height, either in the absence of ICS (7) or at low doses (8) ..
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In our recently reported cross-sectional findings from a large population-based study, girls in late/post puberty had a reduced odds of early adolescent-onset asthma (17) . However, in that study, we did not assess how asthma affects puberty or height. In the present study, we aimed to examine if the exposure of childhood asthma, including timing and phenotypes, and ICS use is either crosssectionally or longitudinally associated with the outcomes of pubertal staging or height.
METHODS
This study is based on the 'Children, Allergy and Environment in Stockholm: An Epidemiological Study (Swedish acronym: BAMSE)' described in detail elsewhere (18) . Swedish-speaking parents of infants born 1994-96 in Stockholm, Sweden were invited to participate. The original cohort (N=4089) was representative of the study catchment area, other than higher rates of parental smoking amongst non-responders (18) .
Parents completed questionnaires when participants were 2 months (baseline) and 1, 2, 4, and 8 years. Participant sex, parental allergy, maternal age or socio-economic status did not differ between participants retained through the 12 year questionnaire and those lost to attrition (19) .
The 12 year questionnaire was completed by both parents and participants, who ranged in age from 11.4-14.6 years. The response rate through the 12 year questionnaire was 82% (3366/4089). After excluding participants with missing pubertal staging (detailed below), the response rate for this study was 67% (n=2746/4089) of the original cohort.
To further enhance questionnaire data, a clinical examination, including blood sampling, was conducted among 2461 participants at 8 years. Sera were analysed for Immunoglobulin E (IgE) to eight common aeroallergens (cat, dog, mites, timothy, birth, mugwort, mould), via Phadiatop® (Thermo Fischer Scientific AB, Uppsala, Sweden).
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Asthma, including Timing and Phenotypes
Parent-reports of wheeze and ICS use in the 12 months prior to each questionnaire except baseline were used to establish asthma status. In keeping with the BAMSE definition of asthma (20) , participants were classified as having asthma based on parent-reports of ≥4 episodes of wheeze or ≥1 episode of wheeze in combination with ICS use in the past 12 months. Although BAMSE uses parent-reports on ICS use, these data have high concordance with dispensing of asthma medications (21) . Asthma status was available for 99% of participants at both 8 years (3397/3431) and 12 years (3339/3366) including all participants at 8 years (n=2668) and 12 years (n=2721) for whom pubertal staging was available. Amongst those with asthma, ICS use in the last 12 months was based on parent-reports at 8 years and 12 years, and was categorised as ICS-treated asthma or non-ICStreated asthma. We also considered asthma timing, defined as follows:
Transient asthma: Asthma at any of the three questionnaires during the first four years (1, 2, 4 years) but not at 8 years.
Persistent asthma: Asthma at any of the three questionnaires during the first four years, and at 8 years.
Late-onset asthma:
No asthma at any of the three questionnaires during the first four years, but asthma at 8 years. As our intent with this definition was to capture the association of the timing of asthma onset and subsequent pubertal staging, we restricted the age of onset to 8 years.
Two asthma phenotypes were also considered, based on data from the clinical examination at 8 years. Sensitisation was defined as an IgE level ≥0.35 kU/L.
Atopic asthma: Asthma and sensitisation to ≥1 aeroallergens at 8 years.
Non-atopic asthma: Asthma but without sensitisation
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Pubertal Staging, Height and Mean Height Increase
At the 12 year questionnaire, participants completed pubertal development questions (22) .
Both sexes were queried about pubic hair growth. Boys were also asked about voice change and facial hair growth. Girls were also asked about breast development and menarche. Points were allocated to each variable to create a composite physical development score (22) . With the exception of menarche, which was dichotomized as no vs. yes, possible responses for each characteristic above included: not yet started; just started; definitely started; complete/fully developed, with 1-4 points allocated respectively. Points were summed for each participant. From these sums, we generated pubertal staging and a composite pubertal score using the Petersen index (22) and mutually exclusive pubertal staging categories (pre-, early-, mid-, late-or post puberty).
For boys, all characteristics contributed equally. Girls reporting menarche by the 12 year questionnaire were categorised as late-or post puberty, regardless of other characteristics. We also considered menarche independent of pubertal staging.
Height was measured at the clinical examination at 8 years. As clinical examinations were not performed at 12 years, we relied on participant-reported height at 12 years. Although measured height is the gold standard, participant-reported height at the ages of our study population approximate measured heights within 0.5-1.5 centimeters (23) . Annual mean height increase (cm) was calculated as the absolute difference in height between 8 and 12 years, divided by the age difference between the questionnaires. This denominator was included to lessen the influence of age on height increase, given that participants ranged from 11.4-14.6 years at the 12 year questionnaire.
Confounding Variables
Potential confounding variables were considered using directed acyclic graphs (DAG). Using DAGs generated via DAGitty (24) , two potential confounders were identified for the association between
Accepted Article
This article is protected by copyright. All rights reserved. asthma and pubertal staging (E- Figure 1 ): Actual age at the 12 year questionnaire, given that age influences pubertal staging and asthma, and BMI z-score at 8 years (25) , given the association between high BMI and pubertal debut (26) and obesity and asthma by the 12 year questionnaire (27) . Similarly, these potential confounders were found for the association between asthma and height, with an additional confounder of socio-economic status, based on parent-reported maternal and paternal highest level of education (E- Figure 2 ).
Statistical Analysis
Chi-squared test was used to establish if differences existed between the non-responders of the original cohort and our study population. Multinomial logistic regression was used for the trichotomous outcome of pubertal staging. Binomial logistic regression was used to analyse associations between asthma and menarche. Linear mixed models with a random intercept were used for the outcome height and linear regression was used for annual mean height increase. In the mixed model age at height measurement was included and we also tested for interaction between asthma and age/sex, to answer the question if the mean difference between the asthma groups differed by age or sex. Odds ratios (OR) and regression coefficients (i.e. mean difference between exposure groups) with corresponding 95% confidence intervals (95%CI) are presented as appropriate. The estimated ORs from the logistic models are presented with and without adjustment for age at the 12 year questionnaire. Analyses on asthma status, timing and phenotypes were performed with subgroups using available data. Analyses on ICS use were restricted to children with asthma. Analyses for pubertal staging were stratified by sex, since the categorisation of puberty differed between boys and girls. Statistical significance was set at p<0.05. Models for annual mean height increase from between 8 and 12 years of age were not adjusted for age at the 12 year questionnaire, as age was already taken into account in that variable.
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As the potential confounder BMI z-score was ascertained based on the clinical examination at 8 years, it was only available for a subgroup. To evaluate the confounding effect of BMI z-score, we conducted sensitivity analyses on this subgroup. Estimates adjusted only for age at the 12 year questionnaire (outcome: pubertal staging) and for age at the respective times of assessment and socio-economic status (outcome: height) were compared to estimates additionally adjusted for BMI z-score at 8 years.
Permission for this study was obtained from the Regional Ethical Review Board in Stockholm, Sweden. Analyses were performed with STATA 11.0 (StatCorp LP, College Station, TX, USA).
RESULTS
Amongst our study population (n=2746), there was a greater proportion of higher socio-economic status and parental allergy and a larger proportion of infants were exclusively breastfed for a minimum of 4 months compared to the non-responders of the original cohort (E- Table 1 ).
Characteristics of the study population are summarized in Table 1 . Few boys (31/1378; 2.2%) but almost half of girls (651/1368; 47.6%) were in late-or post-puberty. Thus, we created different pubertal staging categories for boys (pre-, early-or mid/late puberty (no boys reported post puberty)) and girls (pre/early-, mid-or late/post puberty). Nearly half of the girls had reached menarche. No children without a parent-report of asthma were reported to use ICS.
Associations between asthma, timing and phenotypes at 8 years, and pubertal staging at 12 years are presented in Table 2 (boys) and Table 3 (girls). The direction of the association between asthma timing and pubertal staging tended to be opposite in boys and in girls. However, in adjusted models, asthma was not associated with pubertal staging in boys or girls, or with menarche. 
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This article is protected by copyright. All rights reserved. were no significant differences between boys and girls with regard to the association between height and ICS-treatment (p=0.64) and no interaction with age (p=0.33).
In Figure 2 , we present associations between asthma status, including treatment at 8 years, and mean height (95%CI) at 12 years (Panel A) and annual mean height increase (95%CI) from 8 years to 12 years (Panel B). There were no statistically significant differences in height increase by asthma status or ICS treatment.
In the sensitivity analyses of the subgroup which attended the clinical examination at 8 years and for whom pubertal staging were available (n=2212; 50.5% boys), adjustment for BMI zscore did not substantially alter the point estimates (absolute difference <0.10) for any analyses, compared to adjustment only for age at the 12 year questionnaire (outcome: pubertal staging) or for age at the respective times of assessment and socio-economic status (outcome: height).
DISCUSSION
In this longitudinal, general population birth cohort of Swedish children, asthma at 8 years, including the timing of onset through the first 8 years of life, as well as asthma phenotypes were not associated with pubertal staging at 12 years in either sex, or with menarche. Asthma vs. no asthma was associated with shorter height and there was no statistically significant difference in the association by age or sex. A statistically significant height difference between children with vs.
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without asthma persisted only among those with ICS-treated-asthma, but not those with non-ICStreated asthma. Moreover, children with non-ICS-treated asthma were significantly taller than children with ICS-treated asthma. Our definition of asthma may not have captured disease severity and/or ICS dosage, both of which have been previously reported as influencing height (5, 8, 11 ).
These observations need to be considered when contextualising our findings.
Differences in study design, ages at assessment and operationalisation of asthma may have contributed to collectively inconclusive results. Despite a long-standing interest in the association between asthma and puberty, there are relatively few reports on this topic (5, 10) or the related outcome of menarche (6, 7, 9) and those which exist are conflicting. But, asthma should not be viewed as a single disease. The timing of asthma onset can be viewed as a proxy for asthma severity (28) , with persistent asthma being associated with the most severe disease. As reflected in our study, asthma in early life is often transient. Nonetheless, any asthma-like symptoms in early childhood can impair lung function through the pubertal years (29) . However, those who experience persistent asthma throughout childhood will have long-term poorer lung function (28).
As we lacked data on lung function at 12 years amongst our study participants, the proxy of timing of onset through 8 years as a marker of asthma severity may not have been an adequately sensitive measure to identify differences in pubertal staging at 12 years. However, it does warrant mention that the point estimates for these associations were in opposite directions for boys and girls. This alone is an interesting observation, and warrants further investigation as our study participants proceed through adolescence.
Consideration to atopic status in relation to asthma is also warranted as another phenotype (28) . To our knowledge, only one previous report on atopic asthma in relation to pubertal stages has been published (30). Despite differences in the operationalisation of 'atopic asthma' in our study and elsewhere (30), there is a seemingly consistent association between atopic asthma and later age at menarche.
Our findings on asthma and ICS use on height are consistent with other studies reporting that children with asthma are shorter in stature than their peers without asthma, a difference which disappears in adulthood (5). We used parent-reported data for ICS use. However, these data have high concordance with dispensed of ICS prescriptions during a 12-month window (the time frame for parent-reports in the present study) (21) . Although we lacked data on dosing and severity, our cross-sectional findings parallel a longitudinal study (13) and thus support the theory that both asthma and ICS use may suppress growth in children at 8 and 12 years.
Follow-up, including both questionnaire and clinical data, of BAMSE participants through the 12 year follow-up provides opportunities to create comprehensive definitions of asthma, including phenotypes. Similarly, the use of multiple pubertal characteristics, obtained using a valid instrument (22) permitted the definition of pubertal staging. Both definitions enhance the understanding into the associations between asthma and puberty. Further observation of BAMSE through adolescence and beyond will provide additional opportunities to assess if attained adult height by asthma status.
We acknowledge that our study population consisted of only 67% (2746/4089) of the original cohort, which is a potential weakness of our study. Nonetheless, to our knowledge, this is the largest study on asthma and puberty to date. Moreover, our study population included a higher proportion of children with highly educated parents, parental allergy, and who were more often exclusively breastfed for a minimum of 4 months compared to the non-responders of the original cohort. In addition to largely relying on questionnaire data, we lacked data on asthma severity and dosing or duration of asthma medication use, and could not consider ICS use and pubertal staging or menarche due to small sample sizes. 
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